Logo

Merck Pauses Enrollment in P-III (IMPOWER 22) and (IMPOWER 24) Clinical Trial of Islatravir for Pre-Exposure Prophylaxis of HIV-1 infection

Share this

Merck Pauses Enrollment in P-III (IMPOWER 22) and (IMPOWER 24) Clinical Trial of Islatravir for Pre-Exposure Prophylaxis of HIV-1 infection

Shots:

  • The company temporarily paused enrollment in the P-III (IMPOWER 22 & 24) clinical studies to evaluate islatravir (qm, PO) vs FTC/TDF for pre-exposure prophylaxis in patients at high risk of HIV-1 infection
  • Following the recommendation of PrEP eDMC, the company implements additional monitoring measures for study participants, including increasing the frequency of total lymphocyte and CD4+ T-cell assessments
  • The company is conducting further analyses for other ongoing studies while enrolled patients in the P-III trials will continue to receive the study medicine. Islatravir (MK-8591) is an NRTTIs inhibitor that is designed to prevent HIV-1

Ref: Businesswire | Image: Merck

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions